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Pharmacological activities of some triazinopyrazolothieno 
pyrimidine derivatives
Triazinopyrazolothieno pyrimidine derivatives 1–5 were 
evaluated for their anti-inflammatory, analgesic and anti-
cancer activities and acute toxicity. Anti-inflammatory ac-
tivity of the compounds was studied using the carrageenan 
test. All tested compounds showed analgesic activity, 3-me-
thoxycarbonyl-4,6-dimethyl-8-[(N-methylindolyl)methyl]
pyrimido [5’,4’:4,5]thieno [3’,2’-3,4]pyrazolo [5,1-c]triazine 
(4) showed activity comparable to that of diclofenac. Com-
pounds 1–5 were also screened for anticancer activity on a 
human lung cancer cell line (A549) and a human prostate 
cancer cell line (DU145) using the MTT micro-cultured tet-
razolium assay method. Compound 4 showed also signifi-
cant anticancer activity against both cancer cell lines, com-
parable to that of doxorubicin. The most active compounds 
were tested for their acute toxicity and median lethal doses 
were evaluated.
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Investigations of some triazinopyrazolothieno pyrimidine derivatives and their bio-
logical activities have gained great importance in recent years. Pyrazolopyrimidine de-
rivatives showed the most pronounced activity against Mycobacterium tuberculosis compa-
rable to that of the first line anti-tubercular drug isoniazid (1). Pyrimidine compounds 
showed an indirect anti-angiogenic effect through suppression of the secretion of VEGF 
and TGF-b1 from prostate cancer cells (2) and have, among others, been evaluated as cGMP 
phosphodiesterase inhibitors, but also as kinase inhibitors and potential anti-cancer agents 
(3). Pyrimidine derivatives were also found to have anti-inflammatory activity in BALB/c 
mice with locally induced edema (4). Pyridopyrimidine derivatives were recognized for 
their anticonvulsant and antidepressant activities but showed no neurotoxicity (5). Some 
of pyrimidine derivatives showed in vitro antiplasmodial activity against chloroquine-re-
sistant (CQR) (K1) and drug-sensitive CQS (3D7) strains of Plasmodium falciparum (6). Also, 
pyrimidine derivatives showed good analgesic activity when compared to the standard 
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drug pentazocine (7). Thioxopyrimidine derivatives showed good antifungal activity 
when screened in vitro against Candida albicans, Penicillium ssp. and Aspergillus niger, using 
the agar well disk diffusion method and using amphotericin-B as standard drug (8). Pyr-
azolopyrimidine and pyrimidine derivatives showed good antifungal activity when 
screened against C. albicans, Aspergillus fumigatus, Geotrichum candidum, Syncephalastrum 
racemosum. Also, pyrimidine derivatives exhibited significant activity against bacteria and 
the results were comparable with the standard control (9). New, poly-fused ring pyrazolo-
thieno-pyrimidine derivatives showed good anti-parkinsonian, hypoglycemic and anti-
microbial activities (10). Moreover, some new polycyclic triazolopyrazolo-pyridazine de-
rivatives showed pharmacological activity (11). Herein, some triazinopyrazolothieno 




Triazinopyrazolothieno pyrimidine derivatives 1–5 (Fig. 1) were synthesized accord-
ing to the reported methods (10). 3-Acetyl-4,6-dimethyl-8-[(N-methylindolyl)methyl]py-
rimido [5’,4’:4,5]thieno[3’,2’-3,4]pyrazolo[5,1-c]triazine (1), 3,6-dimethyl-8-[(N-methylin-
dolyl)methyl]pyrimido[5’,4’:4,5]thieno[3’,2’-3,4]pyrazolo[5,1-c]triazin-4-ol (2), 
6-methyl-8-[(N-methylindolyl)methyl]pyrimido[5’,4’:4,5]thieno[3’,2’-3,4]pyrazolo[5,1-c]tri-
azin-3-carbonitrile-4-ol (3), 3-methoxycarbonyl-4,6-dimethyl-8-[(N-methylindolyl)methyl] 
pyrimido[5’,4’:4,5]thieno[3’,2’-3,4]pyrazolo[5,1-c]triazine(4) and 4-amino-6-methyl-8-[(N-
methylindolyl)methyl]pyrimido[5’,4’:4,5]thieno[3’,2’-3,4]pyrazolo[5,1-c]triazine-3-carboni-
trile (5) were afforded by the reaction of the 3-diazopyrazolothienopyrimidine derivative 















Fig. 1. Structures of compounds 1–5.
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ethyl malonate and/or malononitrile, respectively, in the presence of sodium acetate as 
basic medium. Compounds 1–5 were evaluated for anti-inflammatory, analgesic and anti-
cancer activities.
Animals
One hundred and fifty-six male and female Swiss albino mice, five to six weeks old 
and weighing 16–18 g, were obtained from the animal house of Taibah University (Madi-
nah Munawara, KSA) in collaboration with King Saudi University (Riyadh, KSA). Experi-
ments were approved by the Animal Ethical Committee of Taibah University. The animals 
were maintained according to the accepted standards of animal care.
Anti-inflammatory evaluation
Tested triazinopyrazolothieno pyrimidine derivatives 1–5 were dissolved in 0.5 % 
carboxymethyl cellulose (CMC) solution and administered intraperitoneally (i.p.). Ninety-
six mice were divided into sixteen groups, each group consisting of six animals. Edema 
was induced in the right hind paw of all mice by subcutaneous injection of 0.1 mL of 1.0 % 
(m/V) carrageenan in 10 % formal saline (0.85 % NaCl in 10 % formalin). The first group 
was kept as a control and was given the respective volume of the solvent (0.5 mL 10 % 
formal saline). Groups 2–15 were orally administered aqueous suspension of the tested 
compounds in doses of 5 mg kg–1 1 h before carrageenan injection. The last group was 
administered diclofenac sodium (reference drug) in a dose of 5 mg kg–1, orally as aqueous 
suspension. The right paw volume was measured using a digital plethysmometer, directly 
before and 1, 2 and 3 h after administration of the tested compounds (11, 12).
Analgesic activity
Sixty mice were divided into 10 groups, one group was kept as a control (received 
saline), the second group received the vehicle (gum acacia), and the third received diclof-
enac sodium as a reference drug, whereas the other groups received compounds 1–5 via 
subcutaneous administration. The mice were dropped gently into a dry glass beaker of 1 
dm3 capacity maintained at 55 to 55.5 °C (13). Normal reaction time in seconds for all ani-
mals was determined at time intervals of 30, 60 and 90 min. The reaction time is defined 
as the time that elapses from the moment when the mouse reaches the hot beaker till the 
animal licks its feet or jumps out of the beaker (dose 5 mg kg–1). Relative potencies versus 
diclofenac sodium were determined.
Anticancer activity
Test compounds 1–5 were screened for anticancer activity on a human lung cancer cell 
line (A549) and a human prostate cancer cell line (DU145) using the MTT micro-cultured 
tetrazolium assay method (14). Doxorubicin was used as the reference drug. Cells were 
harvested from the logarithmic phase cultures and re-suspended in Dulbecco’s modified 
Eagle’s medium supplemented with 10 % fetal bovine serum. Cell counts were adjusted and 
equal numbers of cells were plated in each well of 96-well culture plates and allowed to 
grow overnight at 37 oC in the presence of 5 % CO2. The cells were treated with test sub-
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stances at various concentrations for 72 hours. In vehicle control culture wells, a maximum 
of 0.5 % DMSO saturated with CO2 was added. Fresh culture medium supplemented with 
test substances was renewed every 24 hours. Thereafter, 0.5 mg mL–1 of MTT reagent was 
added to each well and the micro plate was incubated for further 4 hours at 37 oC in the 
presence of 5 % CO2. Finally, the cells were solubilized by adding a solubilizing solution 
and allowed to incubate at 37 oC overnight. After complete solubilization of formazan crys-
tals, the absorbance was read at 540 nm in a micro plate reader (Bio-Rad, USA). The results 
obtained from quadruplicate wells were used to calculate IC50 of the test compounds.
Acute toxicity
Median lethal doses (LD50) of the most active compounds 2 and 4 were determined in 
mice (15). Groups of male mice, each of six animals, were injected i.p. with graded doses of 
each of the test compounds. The percentage of mortality in each group of animals was de-
termined 24 h after injection. Computation of LD50 was processed by a graphical method.
Statistical analysis
Assay results are shown as the mean ± standard error of the mean (SEM). Statistical 
analyses were carried out using the Sigma Plot software (SPSS Inc., Chicago, USA). One-
way analysis of variance (ANOVA) followed by Tukey’s post-hoc test was used to assess 
the presence of significant differences. Differences were considered statistically significant 
at p ≤ 0.05.
RESULTS AND DISCUSSION
Anti-inflammatory activity
Anti-inflammatory studies after 1, 2 and 3 h showed the same trend of activity of the 

























Fig. 2. Anti-inflammatory activity of compounds 1–5 (dose 5 mg kg–1 b.m, p.o.). Mean ± SEM, n = 6.
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of each of them. After 1 h, compounds 3 and 5 showed weak anti-inflammatory activity (21.4 
± 1.3 and 15.2 ± 1.1 %, resp.), compound 1 showed moderate anti-inflammatory activity (33.2 
± 1.3 %) and compounds 2 and 4 showed strong anti-inflammatory activity (53.1 ± 1.2 and 
51.2 ± 1.4 %) in comparison with flurbiprofen (65.3 ± 1.3 %). After 2 h, compounds 3 and 5 
still showed weak anti-inflammatory activity (24.2 ± 1.2 and 19.6 ± 1.2 %, resp.), compound 
1 moderate activity (35.4 ± 1.3 %) but compounds 2 and 4 possessed strong anti-inflamma-
tory activity (59.2 ± 1.5 and 56.3 ± 1.4 %) compared to the standard drug (72.6 ± 1.1 %). Ac-
cordingly, after 3 h compounds 3 and 5 decreased paw edema by 28.2 ± 1.2 and 24.3 ± 1.1 %, 
compound 1 by 38.7 ± 1.1 %, while compounds 2 and 4 showed the most pronounced reduc-
tion of paw inflammation (66.5 ± 1.3 and 62.1 ± 1.2%) in comparison with the standard drug 
flurbiprofen (77.3 ± 1.4 %) (Fig. 2).
Analgesic activity
Activity of all compounds was normalized relative to the standard drug diclofenac 
sodium with arbitrary unit activity (1.00 ± 0.02) and expressed as a respective ratio. Com-
pounds 1–5 differed in analgesic activity although the same trend of activity increasing 
with time was observed for each of them (Fig. 3). After 30 min, compounds 3 and 5 exerted 
weak (0.35 ± 0.01 and 0.21 ± 0.01), compounds 1 and 2 moderate (0.61 ± 0.01 and 0.62 ± 0.02) 
and compound 4 strong analgesic activity (0.82 ± 0.03) After 60 min, compounds 3 and 5 
still showed weak (0.39 ± 0.02 and 0.25 ± 0.01), compounds 1 and 2 moderate (both 0.65 ± 
0.01) and compound 4 strong analgesic activity (0.83 ± 0.03). After 90 min, compounds 3 
and 5 showed weak (0.43 ± 0.02 and 0.31 ± 0.03), compounds 1 and 2 moderate (0.69 ± 0.02 
and 0.67 ± 0.03), while compound 4 showed strong analgesic activity (0.88 ± 0.01). After 120 
min, compound 5 still showed weak (0.34 ± 0.02), compound 3 moderate (0.46 ± 0.02), com-
pounds 1 and 2 strong analgesic activity (0.73 ± 0.03 and 0.71 ± 0.01), and compound 4 even 
higher analgesic activity (0.92± 0.01) comparable to that of diclofenac.
Fig. 3. Analgesic activity of the tested compounds 1–5 relative to diclofenac (dose 5 mg kg–1 b.m, p.o.). 
Mean ± SEM, n = 6. All results were significantly different (p ≤ 0.05) from the standard (diclofenac) and 
normal control (10 % formal saline) (Tukey’s post-hoc test).
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Anticancer activity
Some of the tested compounds showed significant anticancer activity against the hu-
man lung cancer cell line (A549) and the human prostate cancer cell line (DU145) (Figs. 4 
and 5).
It is evident from Fig. 4 that compound 4 showed the highest activity against the hu-
man lung cancer cell line with IC50 of 9.11 µmol L–1, compounds 1 and 2 were found to be 
moderately effective (19.34 and 18.26 µmol L–1) whereas compounds 3 and 5 were the least 
effective (41.51 and 36.19 µmol L–1) in comparison with the standard drug doxorubicin 
(6.52 µmol L–1).
It is clear from Fig. 5 that the highest activity against the human prostate cancer cell line 
with the IC50 value of 8.42 µmol L–1 was shown by compound 4, whereas compounds 1 and 
2 were found to be moderately effective (16.28 and 14.17 µmol L–1) and compounds 3 and 5 
weakly effective (47.25 and 54.61 µmol L–1) in comparison with doxorubicin (6.87 µmol L–1).
Fig. 4. IC50 values of compounds 1–5 against the human lung cancer cell line (A549). Mean ± SEM, n = 6.
Fig. 5. IC50 values of compounds 1–5 against the human prostate cancer cell line (DU145). Mean ± 
SEM, n = 6.
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Structure activity relationship
Compounds 2 and 4 showed the highest anti-inflammatory activity. This is probably 
due to the presence of hydroxyl-triazinopyrazolo moiety in compound 2 and methoxycar-
bonyl-triazinopyrazolo moiety in compound 4. The latter might also be responsible for the 
highest analgesic and anticancer activity of compound 4.
Acute toxicity
The most active compounds were tested for acute toxicity. LD50 of compounds 2 and 
4 was 4.57 and 5.68 µmol kg–1 bm, resp., whereas that of flurbiprofen was 5.32 µmol kg–1 
(i.p.) (Table I). These LD50 values indicate comparable safety of compounds 2 and 4 to that 
of flurbiprofen.
CONCLUSIONS
In the present investigation, five triazinopyrazolothieno pyrimidine derivatives 1–5 
were screened for their anti-inflammatory, analgesic and anticancer activity. Compound 4 
with an ester functional group showed the strongest anti-inflammatory and analgesic ac-
tivity, comparable to that of diclofenac. The same compounds exerted the highest antipro-
liferative activity against the human lung cancer cell line (A549) and the human prostate 
cancer cell line (DU145), similar to that of the standard drug doxorubicin. The other tested 
compounds exhibited low or moderate activities.
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